AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial

MT Newswires Live

Jun 02, 2025

AstraZeneca (AZN) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.

The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.

The drugmaker said its therapy also delayed quality-of-life deterioration and pain.

AstraZeneca said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540653377"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540653377\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540653377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540653377","market":"sg","top_or_hot":-1,"title":"AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca (AZN) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.</p><p>The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.</p><p>The drugmaker said its therapy also delayed quality-of-life deterioration and pain.</p><p>AstraZeneca said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Says Camizestrant Combo Shows Benefit in Advanced Breast Cancer Phase 3 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-02 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca (AZN) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.</p><p>The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.</p><p>The drugmaker said its therapy also delayed quality-of-life deterioration and pain.</p><p>AstraZeneca said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6522","symbol_name":"化石燃料股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540653377","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540653377","pubTimestamp":1748851661,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca  said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.The drugmaker said its therapy also delayed quality-of-life deterioration and pain.AstraZeneca said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6522":"化石燃料股","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BLZ.SI":"爱文思控股","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4157":"电子设备和仪器","AEIS":"先进能源工业公司","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","BK6088":"石油天然气设备与服务","AZN":"阿斯利康","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4568":"美国抗疫概念","BK4588":"碎股","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC"},"translate_title":"阿斯利康表示卡米司群组合在晚期乳腺癌3期试验中显示出益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"AEIS":1,"BLZ.SI":1},"content_text":"AstraZeneca (AZN) said Sunday a phase 3 study of its camizestrant drug combined with another cancer medicine demonstrated a significant and meaningful improvement in progression-free survival in patients with a type of difficult-to-treat breast cancer.The company said its combination therapy reduced the risk of disease progression or death by 56% compared with standard treatment, with patients experiencing a median progression-free survival of 16 months versus 9.2 months for standard-of-care treatment.The drugmaker said its therapy also delayed quality-of-life deterioration and pain.AstraZeneca said data for key secondary endpoints of time to second disease progression and overall survival were immature at the time of the interim analysis.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}